S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Ambrx Biopharma Stock Price, News & Analysis (NYSE:AMAM)

$12.10
+0.08 (+0.67%)
(As of 12/5/2023 ET)
Compare
Today's Range
$11.56
$12.39
50-Day Range
$8.40
$14.05
52-Week Range
$0.38
$16.86
Volume
980,405 shs
Average Volume
1.70 million shs
Market Capitalization
$764.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.88

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
80.8% Upside
$21.88 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.09mentions of Ambrx Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$28.76 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.43) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

239th out of 948 stocks

Biological Products, Except Diagnostic Industry

29th out of 147 stocks


AMAM stock logo

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Stock Price History

AMAM Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating
Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Analyst Ratings for Ambrx Biopharma
Where Ambrx Biopharma Stands With Analysts
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.88
High Stock Price Target
$32.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+80.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.09 million
Book Value
$3.05 per share

Miscellaneous

Free Float
62,746,000
Market Cap
$764.12 million
Optionable
Not Optionable
Beta
-2.07
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connor J.D. (Age 58)
    CEO, President & Director
    Comp: $509.94k
  • Ms. Sonja Nelson CPA (Age 50)
    Chief Financial Officer
    Comp: $1.18M
  • Mr. Andrew P. Aromando (Age 54)
    Chief Operating Officer
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer & GM of China
  • Mr. Jared Kelly
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Robert Azzara
    Vice President of Human Capital
  • Dr. Sandra Aung Ph.D.
    Chief Clinical Officer
  • Ms. Renu Vaish M.Sc. (Age 56)
    Chief Regulatory Officer














AMAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings
or view top-rated stocks.

What is Ambrx Biopharma's stock price target for 2024?

8 brokerages have issued 12-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $21.88 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts price targets for AMAM
or view top-rated stocks among Wall Street analysts.

How have AMAM shares performed in 2023?

Ambrx Biopharma's stock was trading at $2.27 at the start of the year. Since then, AMAM stock has increased by 433.0% and is now trading at $12.10.
View the best growth stocks for 2023 here
.

What ETFs hold Ambrx Biopharma's stock?

ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

Who are Ambrx Biopharma's major shareholders?

Ambrx Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (3.86%), FMR LLC (2.84%), NWI Management LP (0.26%), Simplex Trading LLC (0.00%), TD Asset Management Inc (0.18%) and Monashee Investment Management LLC (0.11%). Insiders that own company stock include Cormorant Asset Management, Lp, Daniel J O'connor and Sonja Nelson.
View institutional ownership trends
.

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:AMAM) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -